Papillomavirus infections are caused by human papillomaviruses (HPV), a diverse group of DNA viruses that infect epithelial tissues. While many HPV infections are benign and resolve spontaneously, persistent infections with high-risk HPV types can lead to various cancers. HPV is primarily transmitted through direct skin-to-skin contact, and sexual activity is a common mode of transmission. Low-risk HPV types can cause genital warts, while high-risk types are associated with cervical, anal, penile, and oropharyngeal cancers. Cervical cancer, in particular, has a strong association with high-risk HPV infections, prompting the development of HPV vaccines. These vaccines, such as Gardasil and Cervarix, target specific HPV types and have been effective in preventing infection and related cancers. Screening programs, such as Pap smears and HPV testing, aid in early detection and management of HPV-associated diseases. Public health initiatives aim to increase HPV vaccination coverage, raise awareness, and reduce the burden of HPV-related cancers globally. Ongoing research focuses on improving vaccination strategies, understanding the natural history of HPV infections, and developing novel therapeutic interventions.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States